Jonas Schilz

Jonas Schilz has worked at a variety of companies since 2015. In 2021, they began working at iOmx Therapeutics AG as a Scientist I and Group Leader, responsible for internal antibody discovery, covering antibody phage display, high-throughput screenings, antibody engineering, affinity maturation, and protein interaction assays. Jonas also held a Senior Research Associate II role at the same company. From 2018 to 2021, they were a PhD student at Technical University of Munich - Lehrstuhl für Biologische Chemie Prof. Dr. Skerra, where they worked on protein-engineering and characterized antibody-antigen interactions and constructed various antibody formats. In 2017, they were a Master Student at Novartis Institutes for BioMedical Research (NIBR) and an Internship at EUROIMMUN Medizinische Labordiagnostika AG, where they developed a chemiluminescence immunoassay and validated assay components, respectively. In 2016, they were a Visiting Scientist at Novartis Institute for Tropical Diseases, where they worked on the crystal structure of the Dengue virus NS5 RdRp. In 2015, they completed a Bachelor Thesis at Universität zu Lübeck, Institute for Biochemistry, where they worked on structure-based drug design and crystallization of the West-Nile virus NS2B-NS3 protease in complex with a boronic acid inhibitor.

Jonas Schilz completed their Abitur at Max-Planck-Gymnasium Trier from 2003 to 2012. Jonas then went on to pursue a Bachelor of Science (B.Sc.) in Molecular Life Science at Universität zu Lübeck from 2012 to 2015. Following this, they obtained a Master of Science (M.Sc.) in Molecular Life Science at Universität zu Lübeck from 2015 to 2018.